Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 9 for:    CARISOPRODOL

Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain. (Delfos)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03508167
Recruitment Status : Withdrawn (Study design will be reformulated)
First Posted : April 25, 2018
Last Update Posted : July 8, 2019
Sponsor:
Information provided by (Responsible Party):
Ache Laboratorios Farmaceuticos S.A.

Tracking Information
First Submitted Date  ICMJE April 16, 2018
First Posted Date  ICMJE April 25, 2018
Last Update Posted Date July 8, 2019
Estimated Study Start Date  ICMJE January 2020
Estimated Primary Completion Date October 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 16, 2018)
Compare the efficacy and security of Dorilax® plus thermal banc and Placebo plus thermal band [ Time Frame: 8 hours ]
The relief of the pain will be evaluated using a 6 points scale. 0 = no relief; 1 = little relief; 2 = less than half of relief; 3 = more than half of relief; 4 = a lot of relief; 5 = complete relief; The first 2 hours will be evaluated at the center and the other 6 hours the subject will need to provide a diary completed hourly with the pain evaluation.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 16, 2018)
Evaluation of participant satisfaction with treatment [ Time Frame: 72 (+24) hours ]
Satisfaction of the research participant with the treatment, evaluated in the final visit (VF) by means of the visual analog scale of 100 points (EVA of 100mm, being 0mm = totally unsatisfied and 100mm = totally satisfied).
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain.
Official Title  ICMJE National, Phase III, Monocentric, Randomized, Double-blind, Controlled, Parallel, to Evaluate the Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain.
Brief Summary National clinical trial, phase III, monocentric, randomized, double-blind, controlled, parallel, study of superiority, in which two hundred and thirty four (234) participants of both sexes, aged equal or more than 18 years and equal or less than 54 years, will be randomly allocated in one of two treatment groups. The first group will use Dorilax® plus thermal band and the second group will use thermal band plus placebo. The results will show the efficacy and security of Dorilax® and compare the efficiency of Dorilax® and thermal band.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Low Back Pain
Intervention  ICMJE
  • Device: Thermal Band
    Thermal Band used 8 hours per day
  • Drug: Dorilax®

    2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.

    Maximum dosage per day: 6 tablets.

  • Drug: Placebo

    2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.

    Maximum dosage per day: 6 tablets.

Study Arms  ICMJE
  • Experimental: Thermal Band plus Dorilax®
    Interventions:
    • Device: Thermal Band
    • Drug: Dorilax®
  • Thermal Band plus Placebo
    Interventions:
    • Device: Thermal Band
    • Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Withdrawn
Actual Enrollment  ICMJE
 (submitted: July 3, 2019)
0
Original Estimated Enrollment  ICMJE
 (submitted: April 16, 2018)
234
Estimated Study Completion Date  ICMJE November 2020
Estimated Primary Completion Date October 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Participants of both sexes aged ≥ (greater than or equal) to 18 years and ≤ (less than or equal) to 54 years;
  2. Ability to understand and consent their participation in this clinical study, expressed by signing the Informed Consent Form (ICF);
  3. Patient with acute low back pain who responds to the pain period less than or equal to 3 days;
  4. Low back pain in intensity Moderate to severe which corresponds to the severity score at least to 2 scores, evaluated by a 6 scores categoric scale;
  5. No traumatic low back pain (with no traumatic lesion for at least 7 days before randomization)
  6. Low back pain not caused or related to any clinically significant systemic disease, based on investigator evaluation.

Exclusion Criteria:

  1. Any finding of clinical observation (clinical / physical assessment) that is interpreted by the investigating physician as a risk to the participation of the research participant in the clinical study;
  2. Any laboratorial finding that the Investigator consider a risk to subject of the study;
  3. Any finding of a previous imaging examination that the investigator considers to be a risk for clinical study participation;
  4. Known hypersensitivity to the components of the medicines used during the study;
  5. Women in pregnancy or nursing period;
  6. Women who do not agree to use acceptable contraceptive methods (oral contraceptive, intravenous contraceptive, intrauterine device (IUD), hormonal implant, barrier methods, hormonal transdermal patch and tubal ligation); except for those surgically sterile (bilateral oophorectomy or hysterectomy), menopause for at least one year, and participants who report not engaging in sexual practices or non-reproductive practices;
  7. Male participants who did not agree to use acceptable methods of contraception;
  8. Subjects that has participated in clinical trial protocols in the last twelve (12) months (National Board of Health- Resolution 251 of 07 August 1997, Part III, sub-item J), unless the investigator considers that there may be a direct benefit to it;
  9. Subjects who have a relationship of kinship to second degree or any bond with the sponsor or research center employees;
  10. Any serious medical illness, at the discretion of the investigator. For example, sciatica that extends below the knee [associated with numbness, tingling, and acute and irradiated pain]) or other neurological deficits (eg, altered straight leg elevation test, abolished or diminished patellar reflex, function of the intestine and / or bladder); Orthopedic surgery history;Fibromyalgia; Diabetes mellitus; peripheral vascular disease; Osteoporosis; Gastrointestinal ulcers; Bleeding or perforation of the gastrointestinal tract; kidney disease; pulmonary edema; Cardiomyopathy; Liver disease; intrinsic defects of coagulation; Hemorrhagic diseases;
  11. Any skin lesions (eg rash, bruising, swelling, irritation, laceration, excoriation, ulceration) in the lower back.
  12. Use of β-adrenergic blocking agents, antidepressant drugs or supplements that have effects on the central nervous system or that used short- or long-acting analgesic drugs within 24 to 48 hours before randomization, respectively.
  13. History of alcohol and / or illicit drug abuse, involvement in active litigation, or worker's compensation claim involving lumbar spine deficiency, back pain for more than 28 consecutive days, or heat hypersensitivity or NSAIDs.
  14. Subjects with febrile condition (axillary temperature greater or equal to 37.8ºC)
  15. Subjects who have recently had a bacterial infection (last 90 days) that affect the vertebral column, pelvic or abdominal region; as well as participants with a history of bacterial infection that affected the spine in a chronic way;
  16. Subjects with unexplained weight loss (more than 10 kg in the last three months);
  17. Subjects who are performing some type of oral, physical or topical treatment for low back pain (eg acupuncture, local heat and yoga) and / or initiation of physiotherapy program in the last 2 months before the start of therapy. study;
  18. Diabetic subjects, controlled or not.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 54 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03508167
Other Study ID Numbers  ICMJE ACH-DRL-03(01/17)
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Ache Laboratorios Farmaceuticos S.A.
Study Sponsor  ICMJE Ache Laboratorios Farmaceuticos S.A.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Ache Laboratorios Farmaceuticos S.A.
Verification Date July 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP